Neumora Therapeutics’ (NMRA) “Sector Perform” Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada reissued their sector perform rating on shares of Neumora Therapeutics (NASDAQ:NMRA) in a report published on Tuesday,Benzinga reports. Royal Bank of Canada currently has a $4.00 price target on the stock.

A number of other research analysts have also commented on NMRA. William Blair restated an “outperform” rating on shares of Neumora Therapeutics in a research note on Wednesday, January 15th. Needham & Company LLC restated a “buy” rating and issued a $5.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday. Bank of America dropped their price objective on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. HC Wainwright dropped their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, JPMorgan Chase & Co. lowered shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $18.00 to $15.00 in a research note on Tuesday, November 5th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $11.50.

Neumora Therapeutics Stock Up 6.3 %

Shares of NMRA stock opened at $1.52 on Tuesday. Neumora Therapeutics has a 52 week low of $1.35 and a 52 week high of $21.00. The stock has a market capitalization of $245.57 million, a PE ratio of -0.81 and a beta of 2.59. The firm has a 50 day moving average of $2.63 and a two-hundred day moving average of $8.71.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09. Analysts expect that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.

Institutional Trading of Neumora Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Neumora Therapeutics during the fourth quarter worth about $61,000. PNC Financial Services Group Inc. acquired a new stake in shares of Neumora Therapeutics in the fourth quarter valued at approximately $64,000. Quantbot Technologies LP acquired a new stake in shares of Neumora Therapeutics in the fourth quarter valued at approximately $92,000. PEAK6 LLC acquired a new stake in shares of Neumora Therapeutics in the fourth quarter valued at approximately $117,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Neumora Therapeutics in the fourth quarter valued at approximately $135,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.